Working with the US Food and Drug Administration: progress and timelines in understanding and treating patients with eosinophilic esophagitis
- PMID: 22935588
- PMCID: PMC3828675
- DOI: 10.1016/j.jaci.2012.06.051
Working with the US Food and Drug Administration: progress and timelines in understanding and treating patients with eosinophilic esophagitis
Comment on
-
Cross-sector sponsorship of research in eosinophilic esophagitis: a collaborative model for rational drug development in rare diseases.J Allergy Clin Immunol. 2012 Sep;130(3):613-6. doi: 10.1016/j.jaci.2012.07.011. Epub 2012 Jul 31. J Allergy Clin Immunol. 2012. PMID: 22857796
References
-
- Fiorentino R, Liu G, Pariser A, Mulberg A. Cross-Sector Sponsorship of Research in Eosinophilic Esophagitis: A Collaborativ Model for Rational Drug Development in Rare Disease. J Allergy Clin Immunol. 2012;2012 - PubMed
-
- Liacouras CA, Furuta GT, Hirano I, Atkins D, Attwood SE, Bonis PA, et al. Eosinophilic esophagitis: updated consensus recommendations for children and adults. J Allergy Clin Immunol. 2011;128(1):3–20 e6. quiz 1-2. Epub 2011/04/12. - PubMed
-
- Patrick DL, Burke LB, Powers JH, Scott JA, Rock EP, Dawisha S, et al. Patient-reported outcomes to support medical product labeling claims: FDA perspective. Value Health. 2007;10(2):S125–37. Epub 2007/11/13. - PubMed
-
- Konikoff MR, Noel RJ, Blanchard C, Kirby C, Jameson SC, Buckmeier BK, et al. A randomized, double-blind, placebo-controlled trial of fluticasone propionate for pediatric eosinophilic esophagitis. Gastroenterology. 2006;131(5):1381–91. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
